The Human Variable 

Why rheumatoid arthritis is often misdiagnosed or delayed. Learn early RA symptoms, diagnostic gaps, and how CDF-RA™ improves early detection.

A field guide for designing Lyme disease clinical trials that work. Learn how to improve outcomes using adaptive design, co-infection stratification, digital biomarkers, and CYNAERA’s stabilization-first framework.

The Target Readiness Index™ (TRI) introduces a state-dependent framework for CRISPR target prioritization across ME/CFS, Long COVID, Lyme disease, and autoimmune conditions including lupus, type 1 diabetes, Hashimoto’s, and Sjögren’s.

Personalized CRISPR Remission™ for ME/CFS explores customized, individualized gene-editing strategies based on immune state, environmental factors, and neuroimmune instability to enable state-dependent remission in infection-associated chronic conditions. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex, multi-system condition. Personalized CRISPR Remission™ for MECFS is not limited to one editing event or one delivery paradigm.

A state-dependent CRISPR Remission™ framework for systemic lupus erythematosus (SLE) integrating multiomics, AI, environmental modeling (VitalGuard™), and US-CCUC™ prevalence correction to improve timing, safety, and economic outcomes in autoimmune precision medicine.

Personalized CRISPR Remission™ for sarcoidosis introduces a state-dependent precision medicine framework integrating immune biology, environmental exposure, safety modeling, and CYNAERA predictive systems to improve durable response and reduce variability.